Key facts
- Double Blind Bio’s last known valuation is $26.1M (Dec 2025).
- It has raised $7.1M across 1 recorded rounds; the latest was Early Stage VC ($5.6M) in Dec 2025.
- Notable investors include Peterson Partners, Define Ventures.
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Double Blind Bio
Funding rounds
1 roundsAbout Double Blind Bio
Developer of AI (artificial intelligence) agents designed to automate administrative work in clinical trial operations and support more autonomous trials. The company offers intelligent software that connects trial sites, sponsors, and data, enabling clinical research teams to focus on patients and science and move therapeutics from development to availability faster.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 5
- Website
- doubleblindbio.co/
- Ownership
- Privately Held (backing)
Double Blind Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Double Blind Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Double Blind Bio in its N-PORT filings yet. We sweep new filings monthly.